News

News

February 28, 2019

Endpoints News article about Follicum

On 27 February 2019, Endpoints News published an article about Follicum: “Follicum, a Swedish biotech company born to find a treatment for hair loss, now has diabetes in its crosshairs”. Read the article For further information, please contact: Jan Alenfall – CEO, Follicum AB Telephone: +46 46 19 21 97 Email: info@follicum.com About Follicum AB […]

February 7, 2019

Article in BioStock: Follicum have developed a creamlike formulation for treatment of hair loss

BioStock published an article about Follicum’s topical formulation on 7 February 2019 in Swedish. The article is here translated into English. Follicum develops FOL-005 to stimulate hair growth. The peptide-based candidate has recently undergone a phase IIa-study and the company was able to present positive top-line results during the fall. This summer a topical formulation of […]

January 7, 2019

Article in BioStock: Follicum shows rapid progress with diabetes drug candidate

BioStock published an article about Follicum’s diabetes project on 7 January 2019 in Swedish. The article is here translated into English. Follicum is currently running its flagship drug candidate for hair loss, FOL-005, through Phase II clinical trials and the company has recently received key patent extension in the United States as well as an “intention […]

December 18, 2018

A Christmas message from Follicum

The company has had a very intensive autumn and has finalized a number of important activities that have generated much attention. The key milestones are the successful completion of a new phase II study for stimulating hair growth, and at the same time, new preclinical data has been generated in the diabetes project. The results […]

November 1, 2018

Interview Follicum: The results are very exciting and motivate us to start a topical study

Yesterday, Follicum presented top-line results from the First-In-Man scalp study with FOL-005 for stimulation of hair growth. The results confirm that the treatment is well tolerated and show that FOL-005 has the capacity to stimulate hair growth at optimal dosage. BioStock contacted the company’s CEO, Jan Alenfall, for further comments about the study and the […]

November 1, 2018

Follicum presents diabetes research at Bio-Europe in Copenhagen

Follicum AB (“Follicum” or the Company”) today announces that the Company will present results from their diabetes research during the session ”Is the ecosystem of translational metabolic research in greater Copenhagen sustaining a competitive biotech industry?” November 7. The meeting starts with a panel debate lead by Thomas Landh from Novo Nordisk followed by a […]

October 3, 2018

Follicum AB on schedule to present top-line results from the phase IIa study with FOL-005 for hair growth at the end of October 2018

Follicum AB (“Follicum”) reported on August 28, 2018 that all patients in the phase IIa study with FOL-005 for hair growth had completed their treatment. Today Follicum, in according with the company’s communicated time lines, announced it expects to present top-line results from the Phase IIa study by the end of October 2018. Follicum’s Phase […]

October 2, 2018

“Positive data could result in fewer cases of heart attack and stroke in diabetic patients in the future”*

Follicum develops peptide-based medication for hair growth stimulation and diabetes. The combination might at first seem strange, but the company justifies the grouping through the biological connection of the indications involved. BioStock has spoken to professor Anna Hultgårdh, one of the company founders, who clarifies how the two indications are connected and how synergies arise […]

September 27, 2018

Treating hair loss and diabetes

Follicum is developing an anti-diabetic treatment while simultaneously providing treatment for hair loss. At first glance this may seem like an odd combination in a development portfolio, but in fact the two indications are like two beads on a string of pearls. The two endogenously derived peptides FOL-005 and FOL-014 are currently being developed by […]